Skip to main content

Table 1 Characteristics of studies included in the systematic review

From: The effect of hyoscine n- butylbromide on labor progress: A systematic review

STUDYLocationStudy typeAge (y) Mean ± SDNo. of participantsGravidity of participantsTreatment onsetIntervention with dosageControl with dosageDuration of first stage of labour Mean ± SD
HBBPlaceboHBBPlaceboHBBPlacebo
Iravani 2006 [21]IranRCTNANA5050Primigravidas4 cm dilatation and 50% cervical effacementHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously166.56 ± 12.85255.98 ± 25.21
Samuels 2007 [14]West Indies, JamaicaRCT25.0 ± 6.026.9 ± 6.26069Primi- and multigravida4–5 cm dilatationHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously156 ± 121.08228 ± 121.08
Makvand 2010IranRCTNANA6565PrimigravidasEstablished labour,3–4 cm dilatation20 mg Rectal Suppository HBB1 Rectal Suppository placebo141.02 ± 81.86230.09 ± 169.58
Al Qahtan 2011 [34]Saudi ArabiaRCT23.9 ± 4.0424.4 ± 5.365245PrimigravidasEstablished labour,3–4 cm dilatation2 mL HBB (40 mg) intramuscularly2 mL normal saline intramuscularly165 ± 67214 ± 79
Sekhavat 2012 [20]IranRCT26.1 ± 5.426.9 ± 4.89494Multigravidas3–4 cm dilatationHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously186.8 ± 125.6260.4 ± 120.9
Al-Khishali 2012 [31]IraqRCT25.9 ± 5.225.7 ± 5.5100100Primi- and multigravida3–4 cm dilatationHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously167.7 ± 76.2193.8 ± 58.0
Alani 2012 [30]IraqRCT27.62 ± 4.17927.62 ± 3.771130130Multigravidas4 cm dilatationHBB 40 mg (2 ml) intravenouslyNormal saline2 ml intravenously142.69 ± 44.30258.00 ± 23.223
Treviño-Salinas 2015 [25]MexicoRCT25.65 ± 6.55525.37 ± 6.984343Primi- and multigravida4 cm dilatation Or more20 mg of BBH (diluted in 9 ml of saline soalution) intravenously on two occasions with an interval of 1 h10 ml of saline solution intravenously on two occasions with an interval of 1 h151.186 ± 84.657139.93 ± 92.484
Kirim 2015 [10]TurkeyRCT25.90 ± 6.1126.18 ± 5.31197185Primi- and multigravidadilatation of 4 cm and 50% cervical effacementHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously191.13 ± 43.06248.21 ± 66.16
Edessy 2015 [16]EgyptRCT22.5 ± 1.9122.3 ± 1.494442Primigravidas4–5 cm dilatationHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously138 ± 37.2186 ± 46.8
Bashir 2016 [15]PakistanRCTNANA5454Primi- and multigravida4 cm or more cervical dilationHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously178.98 ± 92.44214.74 ± 147.44
Shirazi 2016 [19]IranRCT27(4.56)27.4(3.94)3030Primi- and multigravida (until G4)The active phase of laborHBB 40 mg (2 ml) intravenouslyNormal saline 2 ml intravenously426 ± 279639 ± 237.6
Narappagari 2016 [33]PuducherryRCT24.62 ± 3.5324.67 ± 3.91100100Primi- and multigravidaCervical dilatation of 3–4 cmHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously114 ± 75182 ± 88
Imaralu 2017 [17]NigeriaRCT28.03 ± 4.7928.33 ± 5.348080Primi- and multigravida (until G4)Cervical dilatation of 4 cmHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously365.11 ± 37.32388.46 ± 51.65
Kandil 2017 [18]EgyptRCT23.78 ± 2.6523.21 ± 2.805555PrimigravidasThe active phase of laborHBB 40 mg (2 ml) intramuscularlyNormal saline 2 ml intramuscularly208.16 ± 17.24258.16 ± 15.27
Namaziyan 2017 [35]IranRCTNANA150150PrimigravidasDilatation of 4 cm and 30–40% cervical effacement20 mg HBB (1 ml) and 2 cc distilled water intravenously3 cc water distilled intravenously405.36 ± 108350.87 ± 210
Phahlavani-Sheikhi 2017 [22]IranRCTNANA5550PrimigravidasDilatation of 4 cmHBB 40 mg (2 ml) intravenouslyNormal saline 2 ml intravenously181 ± 59.1208.2 ± 48.5
Barau 2018 [24]NigeriaRCT29.9 ± 4.930.2 ± 4.85964Primi- and multigravidaDilatation of 4–5 cmHBB 20 mg (1 ml) intravenouslyNormal saline 1 ml intravenously279.1 ± 134.0269.3 ± 135.9
Maged 2018 [36]EgyptRCT24.15 ± 3.8224.43 ± 3.734040PrimigravidasDilatation of 3–4 cm and 50% cervical effacementHBB 20 mg (1 ml) + 1 ml saline intravenouslyNormal saline 2 ml intravenously187.73 ± 20.92231.39 ± 33.14
Ibrahim 2019 [32]NigeriaRCT27 ± 525 ± 3102102Primi- and multigravidaDilatation of 4 cmHBB 40 mg (2 ml) intravenouslyNormal saline 2 ml intravenously344 ± 131412 ± 175